---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021861"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:08:40.161999+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M

## Summary
- CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.
- Total revenue $1.4M, down 27% from $1.9M due to discontinuing unprofitable pathology services.
- Net loss $3.6M ($0.81/share) vs $2.7M ($4.80/share) in Q1 2025; cash $3.1M.
- Physician offices ordering CyPath Lung increased 69% YoY; company expects acceleration.
- Launched DoD-funded longitudinal trial; Brooke Army Medical Center study for asthma/COPD companion tests.

## SEC filing metadata
- accession: 0001493152-26-021861
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226021861/0001493152-26-021861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226021861/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021861
- JSON: https://secwatch.observer/filing/0001493152-26-021861.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021861.txt

## Source-grounded claims
- claim_id: 98b5933c74c8ce47ce64b4b6476b6b148c1068b6
  claim: bioAffinity Technologies, Inc. reported first quarter ended March 31, 2026 results: revenue $1.4 million.
  evidence_excerpt: Lung testing revenue increased approximately 114% to $361,000 , compared to $169,000 in the first quarter of 2025. ● Total consolidated revenue decreased approximately 27% to $1.4 million , compared to $1.9 million for the first quarter of 2025, resulting from the discontinuation of certain unprofitable pathology services in March 2025 to focus on higher margin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315226021861/0001493152-26-021861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.